Biomx Inc represents a strong commitment to innovation, research, and breakthroughs in the field of microbiome therapeutics. The company's corporate philosophy is centered around developing personalized treatments to address unmet medical needs related to serious diseases and conditions caused by dysbiosis within the human microbiome. Biomx Inc strives to harness the power of the microbiome to improve patient outcomes and quality of life. Through cutting-edge technologies and strategic partnerships, Biomx Inc aims to advance the understanding and utilization of the microbiome, paving the way for innovative therapeutic solutions.

Biomx Inc is primarily present in the United States, with headquarters located in Ness Ziona, Israel.

Biomx Inc has achieved several significant milestones. The company has successfully developed a unique and innovative biotechnology platform that focuses on engineered phage products for the treatment of various diseases. Biomx Inc has also formed strategic partnerships with leading pharmaceutical companies, further enhancing their research and development capabilities. Notably, the company has advanced its clinical programs and successfully initiated Phase 1b/2a clinical studies, demonstrating promising results. Additionally, Biomx Inc has raised substantial funding through successful financing rounds, enabling them to support their cutting-edge research and reach key developmental targets. These achievements highlight Biomx Inc's commitment to advancing its novel therapeutic solutions and positioning itself as a key player in the biotechnology industry.

Biomx Inc is a biotechnology company specializing in the development of novel therapeutics using customized phage-based microbiome engineering. Founded in 2015, Biomx is dedicated to harnessing the power of the human microbiome to treat various diseases. With a focus on inflammatory bowel disease (IBD) and cancer, Biomx aims to revolutionize the field of microbiome-based therapeutics. Through their proprietary platform, Biomx engages in comprehensive research and development, leveraging cutting-edge technologies and scientific expertise. By understanding the intricate relationship between the human microbiome and diseases, Biomx is committed to delivering innovative, personalized therapies that have the potential to transform patient outcomes and improve lives.

The main competitors of Biomx Inc in the market include companies like Vedanta Biosciences, Seres Therapeutics, and Second Genome.

Biomx Inc is primarily active in the field of microbiome-based therapeutics.

Biomx Inc operates with a business model focused on the development of novel therapeutics using its proprietary microbiome-based technology platform. The company utilizes advanced computational tools and synthetic biology to identify and modify specific bacterial strains within the human microbiome, aiming to treat various diseases. By leveraging the potential of bacteria living within the body, Biomx Inc seeks to offer innovative solutions for conditions such as inflammatory bowel disease (IBD), cancer, and immuno-oncology. Through targeted modifications and interventions, Biomx Inc aims to harness the power of the microbiome to improve human health and address unmet medical needs.

P/E odnos Biomx iznosi -0,52.

KUV kompanije Biomx iznosi 0.

AlleAktien kvalitativni skor za Biomx je 1/10.

Prihod trenutno ne može biti izračunat za Biomx.

Dobit očekivana Biomx je -34,89 mil. USD.

The company Biomx Inc is a biotechnology company that specializes in the development and application of microbiome-related therapies. The various divisions of the company include research, development, and marketing of bacterial therapies and diagnostic tools for various diseases such as chronic inflammatory bowel disease, cancer, and skin diseases.

Biomx isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Biomx trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Biomx je US09090D1037.

WKN od Biomx je A2P9A0.

Oznaka za praćenje akcija kompanije Biomx je PHGE.

U poslednjih 12 meseci, Biomx je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Biomx će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Biomx trenutno iznosi .

Biomx isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Biomx je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Biomx se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Biomx od 4. 7. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 4. 7. 2024..

Isplata poslednje dividende izvršena je 4. 7. 2024..

U godini 2023 kompanija Biomx je isplatila 0 USD kao dividende.

Dividende od Biomx se isplaćuju u USD.